<?xml encoding="utf-8" ?> Editor’s note: This story and headline have been corrected to reflect that BNT122 is a BioNTech and ...

Merck (MRK) stock slips as RBC Capital Markets cuts on valuation while Morgan Stanley upgrades on trial data for Moderna ...

Merck (MRK) stock surged 12.12% after positive Phase 3 melanoma trial results with Moderna showed improved survival rates for ...

Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so ...

MRK remains a defensive, yield-generating diversification play, but near-term upside appears constrained by valuation and ...

A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, ...

A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, ...

Among U.S. large-cap drugmakers, one name has clearly outrun the pack in 2026 so far. Merck (NYSE:MRK | MRK Price Prediction) ...

Merck, which makes the popular cancer treatment Keytruda, is poised to gain ground as its pipeline drugs get close to coming ...

Oncology R&D organization Sarah Cannon Research Institute (SCRI) announced a collaboration with Merck & Co. to bolster patient access to community-based oncology trials. | Oncology R&D organization ...